Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034

Core Insights - Biocytogen Pharmaceuticals has announced that its partner IDEAYA Biosciences has initiated the first patient dosing in a Phase 1 clinical trial for IDE034, a bispecific antibody-drug conjugate targeting B7H3/PTK7 [1] Company Summary - Biocytogen Pharmaceuticals is a global biotechnology company focused on the research and development of novel antibody-based drugs utilizing innovative technologies [1] - IDEAYA Biosciences, a partner of Biocytogen, is conducting the clinical trial for IDE034, which is currently in the dose-escalation and expansion phase [1]